DDInter1800 DDInter364
Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The beta subunit (TSHB) best
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Sulfacetamide
Sulfacetamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dulaglutide
Dulaglutide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Sulfacetamide (Compound) and Sulfacetamide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Probenecid and Probenecid (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Thyrotropin alfa may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)